Request Demo
Recent blog posts
Latest Hotspot
8 min read
Skin Prick Solution for Cat Fur (Wolwo Bio-Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Skin Prick Solution for Cat Fur (Wolwo Bio-Pharmaceutical): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Idiopathic Pulmonary Fibrosis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Idiopathic Pulmonary Fibrosis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Skin Prick Solution for Platanus Acerifolia Pollen (Wolwo Bio-Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Skin Prick Solution for Platanus Acerifolia Pollen (Wolwo Bio-Pharmaceutical): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP.
Latest Hotspot
8 min read
COPD Disease Modification Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 COPD Disease Modification clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Citrulline Malate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Citrulline Malate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Severe Eosinophilic Asthma Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Severe Eosinophilic Asthma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Tetravalent vaccine (ApicHope Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Tetravalent dengue virus vaccine(Instituto Butantan): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Factor VIII (Bohui Bio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Factor VIII (Bohui Bio): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Asthma Biologics Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Asthma Biologics clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Influenza virus subunits vaccine (Chengda) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Influenza virus subunits vaccine (Chengda): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Invasive Fungal Infections Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Invasive Fungal Infections clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Rabies Vaccine(Vero Cell)for Human Use (Aleph Biomedical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Human rabies vaccine(chicken embryo fibroblasts) (King-cell): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.